東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Investigating the Role of Post-trans...

Kistler, Samantha Kathleen.

Linked to FindBook

Google Book

Amazon

博客來

Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain./
Author:	Kistler, Samantha Kathleen.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	190 p.
Notes:	Source: Dissertations Abstracts International, Volume: 80-12, Section: B.
Contained By:	Dissertations Abstracts International80-12B.
Subject:	Cellular biology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13814632
ISBN:	9781392201558

Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain.
Kistler, Samantha Kathleen.

Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 190 p.

Source: Dissertations Abstracts International, Volume: 80-12, Section: B.

Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2019.

This item must not be added to any third party search indexes.

Ras proteins are the most commonly mutated oncoproteins in cancer (~30%). Oncogenic, activating Ras mutations are known drivers of the deadliest human cancers, including lung, pancreatic and colorectal cancers. Ras proteins function as critical regulators of cellular growth by acting as molecular switches, cycling between active, GTP- and inactive, GDP-bound states. In their active form, Ras proteins signal through downstream pathways that regulate cellular growth, differentiation and apoptosis. Early attempts to target Ras proteins (farnesyltransferase inhibitors) were directed toward inhibiting key carboxyl (C)-terminal lipid post-translational modifications (PTMs), which are crucial for proper Ras localization and function at the cellular membrane. Despite their failure, FTIs represent the first direct targeting efforts of Ras proteins.Promising new classes of anti-cancer drugs directed at targeting the dysregulation of PTM status in cancers (kinase inhibitors, histone deacetylase inhibitors, HDACi and methyltransferase inhibitors) have demonstrated multiple clinical successes in recent years. PTMs have been demonstrated to alter protein stability and localization as well as protein-protein interactions in several non-histone cancer-related proteins. While PTMs have been extensively studied in the C-terminus of Ras proteins, their role remains poorly understood in the core Ras guanine nucleotide binding domain (GTPase domain). Monoubiquitylation and acetylation within the core Ras GTPase domain have been demonstrated to modulate Ras protein activity, signaling and tumorigenesis, suggesting that PTMs in this region are capable of regulating Ras behavior. Further, aberrant dysregulation in the balance of PTMs has been characterized in several cancer types, including the Ras-driven pancreatic cancer. It is therefore reasonable that Ras PTMs may present a novel avenue for therapeutic targeting in cancer. Despite more than three decades of research, Ras has remained an elusive target for cancer therapy.We have recently identified novel sites of PTMs in Ras proteins at highly conserved residues within the core GTPase domain. Herein, we present highly innovative and novel methods of generating both acetyl- and methyl-lysine in intact Ras proteins. With the combined use of biochemical, structural, cellular and computational data, we provide mechanistic insight into the regulation Ras proteins by PTMs and also provide rationale for novel therapeutic targeting approaches in Ras-driven cancers.

ISBN: 9781392201558Subjects--Topical Terms:

3172791
Cellular biology.

Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain.
LDR:03735nmm a2200349 4500 001 2210755
005 20191121124307.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392201558
035 $a (MiAaPQ)AAI13814632
035 $a (MiAaPQ)unc:18391
035 $a AAI13814632
040 $a MiAaPQ $c MiAaPQ
100 1 $a Kistler, Samantha Kathleen. $3 3437890
245 1 0 $a Investigating the Role of Post-translational Modifications in the Core Ras GTPase Domain.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 190 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-12, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Campbell, Sharon.
502 $a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2019.
506 $a This item must not be added to any third party search indexes.
506 $a This item must not be sold to any third party vendors.
520 $a Ras proteins are the most commonly mutated oncoproteins in cancer (~30%). Oncogenic, activating Ras mutations are known drivers of the deadliest human cancers, including lung, pancreatic and colorectal cancers. Ras proteins function as critical regulators of cellular growth by acting as molecular switches, cycling between active, GTP- and inactive, GDP-bound states. In their active form, Ras proteins signal through downstream pathways that regulate cellular growth, differentiation and apoptosis. Early attempts to target Ras proteins (farnesyltransferase inhibitors) were directed toward inhibiting key carboxyl (C)-terminal lipid post-translational modifications (PTMs), which are crucial for proper Ras localization and function at the cellular membrane. Despite their failure, FTIs represent the first direct targeting efforts of Ras proteins.Promising new classes of anti-cancer drugs directed at targeting the dysregulation of PTM status in cancers (kinase inhibitors, histone deacetylase inhibitors, HDACi and methyltransferase inhibitors) have demonstrated multiple clinical successes in recent years. PTMs have been demonstrated to alter protein stability and localization as well as protein-protein interactions in several non-histone cancer-related proteins. While PTMs have been extensively studied in the C-terminus of Ras proteins, their role remains poorly understood in the core Ras guanine nucleotide binding domain (GTPase domain). Monoubiquitylation and acetylation within the core Ras GTPase domain have been demonstrated to modulate Ras protein activity, signaling and tumorigenesis, suggesting that PTMs in this region are capable of regulating Ras behavior. Further, aberrant dysregulation in the balance of PTMs has been characterized in several cancer types, including the Ras-driven pancreatic cancer. It is therefore reasonable that Ras PTMs may present a novel avenue for therapeutic targeting in cancer. Despite more than three decades of research, Ras has remained an elusive target for cancer therapy.We have recently identified novel sites of PTMs in Ras proteins at highly conserved residues within the core GTPase domain. Herein, we present highly innovative and novel methods of generating both acetyl- and methyl-lysine in intact Ras proteins. With the combined use of biochemical, structural, cellular and computational data, we provide mechanistic insight into the regulation Ras proteins by PTMs and also provide rationale for novel therapeutic targeting approaches in Ras-driven cancers.
590 $a School code: 0153.
650 4 $a Cellular biology. $3 3172791
650 4 $a Biochemistry. $3 518028
650 4 $a Biophysics. $3 518360
690 $a 0379
690 $a 0487
690 $a 0786
710 2 $a The University of North Carolina at Chapel Hill. $b Pharmaceutical Sciences. $3 1285238
773 0 $t Dissertations Abstracts International $g 80-12B.
790 $a 0153
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13814632